11.66
-0.17 (-1.44%)
| Penutupan Terdahulu | 11.83 |
| Buka | 11.51 |
| Jumlah Dagangan | 1,489,042 |
| Purata Dagangan (3B) | 2,498,542 |
| Modal Pasaran | 1,325,357,184 |
| Harga / Buku (P/B) | 2.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| EPS Cair (TTM) | -3.37 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.81% |
| Nisbah Semasa (MRQ) | 15.60 |
| Aliran Tunai Operasi (OCF TTM) | -292.37 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -189.47 M |
| Pulangan Atas Aset (ROA TTM) | -50.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -88.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Dyne Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.75 |
|
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.69% |
| % Dimiliki oleh Institusi | 101.05% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (Chardan Capital, 328.82%) | Beli |
| 50.00 (BMO Capital, 328.82%) | Beli | |
| 50.00 (Scotiabank, 328.82%) | Beli | |
| Median | 49.00 (320.24%) | |
| Rendah | 17.00 (JP Morgan, 45.80%) | Pegang |
| Purata | 42.17 (261.66%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 12.21 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 09 May 2025 | 50.00 (328.82%) | Beli | 11.41 |
| 17 Mar 2025 | 50.00 (328.82%) | Beli | 12.31 | |
| HC Wainwright & Co. | 09 May 2025 | 38.00 (225.90%) | Beli | 11.41 |
| 17 Mar 2025 | 46.00 (294.51%) | Beli | 12.31 | |
| JP Morgan | 21 Mar 2025 | 17.00 (45.80%) | Pegang | 12.08 |
| BMO Capital | 12 Mar 2025 | 50.00 (328.82%) | Beli | 12.36 |
| Scotiabank | 07 Mar 2025 | 50.00 (328.82%) | Beli | 12.40 |
| Piper Sandler | 28 Feb 2025 | 48.00 (311.66%) | Beli | 13.61 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |